Literature DB >> 18557243

Antazoline in the treatment of cardiac arrhythmias.

S S Shah1, C H Vaidya, H V Doshi.   

Abstract

Antazoline was administered in sixty-five episodes of various types of cardiac arrhythmia. A complete suppression of the ectopic beats was achieved in five out of six episodes of premature atrial systoles and in twenty-one of the twenty-four episodes of ventricular premature systoles. Conversion to sinus rhythm was observed in seven out of ten and four out of five episodes of paroxysmal atrial and nodal tachycardia respectively. Six out of ten episodes of ventricular tachycardia were controlled by intravenous therapy. However, the drug proved to be ineffective in cases of atrial fibrillation. The side-effects were few and transitory, consisting of nausea, vomiting and drowsiness.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 18557243      PMCID: PMC2495299          DOI: 10.1136/pgmj.48.559.304

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  11 in total

1.  A CLINICAL TRIAL OF ANTAZOLINE IN THE TREATMENT OF ARRHYTHMIAS.

Authors:  E W REYNOLDS; W M BAIRD; M E CLIFFORD
Journal:  Am J Cardiol       Date:  1964-10       Impact factor: 2.778

Review 2.  NEWER AGENTS IN THE TREATMENT OF CARDIAC ARRHYTHMIAS.

Authors:  L S DREIFUS; M D RABBINO; Y WATANABE
Journal:  Med Clin North Am       Date:  1964-03       Impact factor: 5.456

3.  AN EVALUATION OF ANTAZOLINE AS AN ANTI-ARRHYTHMIC AGENT.

Authors:  R G KIGER
Journal:  J S C Med Assoc       Date:  1964-02

4.  ANTIARRHYTHMIC AND ANTIFIBRILLARY ANTAZOLINE: A CLINICAL STUDY.

Authors:  G R HERRMANN; C R SECREST; G J VILBIG; R A UINT; A W HERRMANN
Journal:  J La State Med Soc       Date:  1964-05

5.  A clinical evaluation of the antiarrhythmic properties of antazoline.

Authors:  L LEON-SOTOMAYOR
Journal:  Am J Cardiol       Date:  1963-05       Impact factor: 2.778

6.  Evaluation of the antiarrhythmic properties of antazoline. A preliminary study.

Authors:  S R KLINE; L S DREIFUS; Y WATANABE; T F McGARRY; W LIKOFF
Journal:  Am J Cardiol       Date:  1962-04       Impact factor: 2.778

7.  The cardiac action of the antihistamine compounds.

Authors:  J K MCKECHNIE
Journal:  S Afr Med J       Date:  1952-07-26

8.  Experience in conversion of cardiac arrhythmia with antazoline (antistin R ).

Authors:  H V Srinivas; J A Antani
Journal:  J Assoc Physicians India       Date:  1971-05

9.  A clinical evaluation of antazoline in cardiac arrhythmia.

Authors:  J A Antani
Journal:  Indian Heart J       Date:  1971-07

10.  Some pharmacological properties of 2(phenylbenzylaminomethyl)-imidazoline hydrochloride (antistine), an antihistamine.

Authors:  B N CRAVER; W BARRETT; A CAMERON; E HERROLD; F F YONKMAN
Journal:  Ann Allergy       Date:  1951 Jan-Feb
View more
  5 in total

1.  Intravenous antazoline, a first-generation antihistaminic drug with antiarrhythmic properties, is a suitable agent for pharmacological cardioversion of atrial fibrillation induced during pulmonary vein isolation due to the lack of influence on atrio-venous conduction and high clinical effectiveness (AntaEP Study).

Authors:  Michal M Farkowski; Aleksander Maciag; Ilona Kowalik; Marek Konka; Hanna Szwed; Mariusz Pytkowski
Journal:  Br J Clin Pharmacol       Date:  2019-05-23       Impact factor: 4.335

Review 2.  Anti-Arrhythmic Agents in the Treatment of Atrial Fibrillation.

Authors:  Omar F Hassan; Jassim Al Suwaidi; Amar M Salam
Journal:  J Atr Fibrillation       Date:  2013-06-30

3.  Antazoline-insights into drug-induced electrocardiographic and hemodynamic effects: Results of the ELEPHANT II substudy.

Authors:  Roman Piotrowski; Joanna Giebułtowicz; Jakub Baran; Agnieszka Sikorska; Dagmara Gralak-Łachowska; Małgorzata Soszyńska; Piotr Wroczyński; Piotr Kułakowski
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-02-25       Impact factor: 1.468

4.  Effect of Antazoline on Electrophysiological Properties of Atrial Muscle and Conduction System of the Heart.

Authors:  Bartłomiej Jacek Bińkowski; Marcin Makowski; Paweł Kubiński; Andrzej Lubiński
Journal:  Cardiovasc Drugs Ther       Date:  2018-04       Impact factor: 3.727

5.  Clinical efficacy of antazoline in rapid cardioversion of paroxysmal atrial fibrillation--a protocol of a single center, randomized, double-blind, placebo-controlled study (the AnPAF Study).

Authors:  Michal M Farkowski; Aleksander Maciag; Rafal Dabrowski; Mariusz Pytkowski; Ilona Kowalik; Hanna Szwed
Journal:  Trials       Date:  2012-09-11       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.